FILE:ALXN/ALXN-8K-20061215120840.txt.gz
EVENTS:	Cost Associated with Exit or Disposal Activities
TEXT:
ITEM: Cost Associated with Exit or Disposal Activities
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( General Instruction A.2. below):
see
 
 
 
 
 
Item 2.05 Costs Associated with Exit or Disposal Activities.
On December 11, 2006, Alexion Pharmaceuticals, Inc. (the "Company") notified its San Diego based subsidiary, Alexion Antibody Technologies, Inc. ("AAT"), that all activities and technologies at AAT will be transferred to the Company's main offices and laboratories in Cheshire, Connecticut. The 27 employees based at AAT will be terminated as of December 31, 2006. The Company expects that in connection with closing AAT and terminating AAT employees it will recognize expenses in 2006 of approximately $6.0 to $8.0 million, including approximately (i) $4.8 to $6.1 million relating to employee termination costs; (ii) $0.9 to $1.3 million relating to termination of leases and other contracts; and (iii) $0.3 to $0.6 million relating to disposition and abandonment of assets. The Company estimates its total cash charges in connection with closing AAT and terminating ATT employees will be approximately $2.3 million.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


